Biogen (BIIB) Competitors $135.49 +1.34 (+1.00%) Closing price 04:00 PM EasternExtended Trading$135.24 -0.25 (-0.18%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. REGN, ALNY, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, HALO, and RGENShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Biogen vs. Regeneron Pharmaceuticals Alnylam Pharmaceuticals United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Repligen Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability. Do analysts recommend REGN or BIIB? Regeneron Pharmaceuticals presently has a consensus target price of $836.48, indicating a potential upside of 59.74%. Biogen has a consensus target price of $191.30, indicating a potential upside of 41.22%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 3 Strong Buy rating(s) 2.85Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38 Does the media prefer REGN or BIIB? In the previous week, Regeneron Pharmaceuticals had 20 more articles in the media than Biogen. MarketBeat recorded 29 mentions for Regeneron Pharmaceuticals and 9 mentions for Biogen. Biogen's average media sentiment score of 1.20 beat Regeneron Pharmaceuticals' score of 0.44 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of REGN or BIIB? 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer REGN or BIIB? Biogen received 258 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 66.95% of users gave Regeneron Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRegeneron PharmaceuticalsOutperform Votes156666.95% Underperform Votes77333.05% BiogenOutperform Votes182471.28% Underperform Votes73528.72% Which has stronger earnings and valuation, REGN or BIIB? Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$14.09B4.01$4.41B$39.2813.33Biogen$9.82B2.02$1.63B$10.1313.37 Which has more risk & volatility, REGN or BIIB? Regeneron Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Is REGN or BIIB more profitable? Regeneron Pharmaceuticals has a net margin of 31.07% compared to Biogen's net margin of 16.87%. Regeneron Pharmaceuticals' return on equity of 16.32% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals31.07% 16.32% 12.76% Biogen 16.87%14.98%8.76% SummaryRegeneron Pharmaceuticals beats Biogen on 15 of the 19 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.87B$3.11B$5.57B$8.65BDividend YieldN/A1.59%5.27%4.19%P/E Ratio12.1233.8027.3520.19Price / Sales2.02479.10413.54162.98Price / Cash6.09168.6838.2534.64Price / Book1.183.497.164.73Net Income$1.63B-$72.35M$3.23B$247.88M7 Day Performance2.74%10.36%6.29%4.30%1 Month Performance14.60%24.12%15.03%10.61%1 Year Performance-40.06%-15.32%32.66%15.07% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.7996 of 5 stars$135.49+1.0%$191.30+41.2%-40.5%$19.85B$9.82B12.118,720Positive NewsREGNRegeneron Pharmaceuticals4.8323 of 5 stars$496.76+1.3%$847.40+70.6%-48.4%$53.62B$14.09B12.9711,900Analyst ForecastHigh Trading VolumeALNYAlnylam Pharmaceuticals3.9381 of 5 stars$304.12-0.1%$319.17+4.9%+99.0%$39.66B$2.35B-140.172,000UTHRUnited Therapeutics4.9653 of 5 stars$325.81+2.2%$393.00+20.6%+19.4%$14.71B$2.99B14.32980Trending NewsInsider TradeAnalyst RevisionINCYIncyte4.2963 of 5 stars$65.47+0.6%$73.60+12.4%+18.1%$12.68B$4.41B242.582,320Positive NewsNBIXNeurocrine Biosciences4.9489 of 5 stars$123.93+0.7%$162.00+30.7%-6.8%$12.27B$2.41B37.691,200Analyst RevisionEXELExelixis4.5521 of 5 stars$42.70-0.8%$38.94-8.8%+96.2%$11.64B$2.30B24.121,220Positive NewsBMRNBioMarin Pharmaceutical4.8958 of 5 stars$57.28-1.4%$93.45+63.2%-29.5%$10.99B$2.95B26.053,080Positive NewsAnalyst RevisionEXASExact Sciences4.385 of 5 stars$55.66-1.1%$70.90+27.4%+27.3%$10.49B$2.83B-9.996,400Positive NewsHALOHalozyme Therapeutics4.8617 of 5 stars$55.17-1.6%$61.90+12.2%+6.9%$6.80B$1.08B16.09390RGENRepligen4.8297 of 5 stars$119.50+1.2%$173.25+45.0%-9.7%$6.72B$650.43M-234.382,020 Related Companies and Tools Related Companies Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors United Therapeutics Competitors Incyte Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Repligen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s Secret WeaponThe Trump-Elon War Could Trigger an Economic Collapse - Here's Your Only Safe Exit This isn't just a war of...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIIB Stock Free BIIB Stock Alerts